FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO has a total of 18 patent applications. Its first patent ever was published in 2015. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are JP AGENCY OF NAT CANCER CT, ZOLTAN LAB LLC and ICAHN SCHOOL MED MOUNT SINAI.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 2 | |
#4 | Australia | 1 | |
#5 | China | 1 | |
#6 | Israel | 1 | |
#7 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry | |
#4 | Agriculture | |
#5 | Measurement | |
#6 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds | |
#4 | Microorganisms | |
#5 | Animal care | |
#6 | Peptides | |
#7 | Enzymes | |
#8 | Analysing materials | |
#9 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Blanco-Aparicio Carmen | 10 |
#2 | Blasco Marhuenda Maria Antonia | 6 |
#3 | Mendez Pertuz Marinela | 5 |
#4 | Rivero Buceta Virginia | 5 |
#5 | Pastor Fernandez Joaquin Angel | 5 |
#6 | Martinez Rodriguez Paula | 5 |
#7 | Gomez-Casero Esteban Elena | 5 |
#8 | Bejarano Bosque Leire | 5 |
#9 | Garcia-Beccaria Maria | 5 |
#10 | Martinez Gonzalez Sonia | 4 |
Publication | Filing date | Title |
---|---|---|
WO2020020942A1 | Combined therapy inhibiting expression, activity and/or function of epidermal growth factor receptor and c-raf against cancer | |
EP3640329A1 | Gene editing based cancer treatment | |
EP3623009A1 | Modulation of trf1 for brain cancer treatment | |
WO2020052772A1 | Modulation of trf1 for brain cancer treatment | |
EP3623370A1 | Novel trf1 modulators and analogues thereof | |
EP3598973A1 | Combined therapy against cancer | |
EP3341376A1 | Condensed tricyclic compounds as protein kinase inhibitors | |
EP3485914A1 | Telomerase reverse transcriptase-based therapies |